Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene

Cancer Research

Volumn 62, Issue 22, 2002, Pages 6712-6716

  Ueno, Naoto T ^a   Bartholomeusz, Chandra ^a   Xia, Weiya ^a   Anklesaria, Pervin ^b   Bruckheimer, Elizabeth M ^b   Mebel, Elise ^b   Paul, Ralph ^b   Li, Song ^c   Yo, George H ^d   Huang, Leaf ^c   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Targeted Genetics Corporation   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA; LIPOSOME; PACLITAXEL; PROTAMINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; E1A GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE THERAPY; HUMAN; HUMAN CELL; INTRATUMORAL DRUG ADMINISTRATION; METASTASIS; MITOSIS INHIBITION; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE NEU; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRUS E1A PROTEINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; DNA; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; LIPOSOMES; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037112449     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mymryk, J. S. Tumor suppressive properties of the adenovirus 5 E1A oncogene. Oncogene, 13: 1581-1589, 1996
2. Deng, J., Xia, W., and Hung, M. C. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. Oncogene, 17: 2167-2175, 1998
3. Shao, R., Xia, W., and Hung, M. C. Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. Cancer Res., 60: 3123-3126, 2000
4. Ueno, N. T., Bartholomeusz, C., Herrmann, J. L., Estrov, Z., Shao, R., Andreeff, M., Price, J., Paul, R. W., Anklesaria, P., Yu, D., and Hung, M. C. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3. ip1 through apoptosis involving the caspase-3 pathway. Clin. Cancer Res., 6: 250-259, 2000
5. Shao, R., Karunagaran, D., Zhou, B. P., Li, K., Lo, S. S., Deng, J., Chiao, P., and Hung, M. C. Inhibition of nuclear factor-κB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem., 272: 32739-32742, 1997
6. Hortobagyi, G. N., Ueno, N. T., Xia, W. Y., Zhang, S., Wolf, J. K., Putnam, J. B., Weiden, P. L., Willey, J. S., Carey, M., Branham, D. L., Payne, J. Y., Tucker, S. D., Bartholomeusz, C., Kilbourn, R. G., De Jager, R. L., Sneige, N., Katz, R. L., Anklesaria, P., Ibrahim, N. K., Murray, J. L., Theriault, R. L., Valero, V., Gershenson, D. M., Bevers, M. W., Huang, L., and et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: A phase I clinical trial. J. Clin. Oncol., 19: 3422-3433, 2001
7. Yoo, G. H., Hung, M. C., Lopez-Berestein, G., LaFollette, S., Ensley, J. F., Carey, M., Batson, E., Reynolds, T. C., and Murray, J. L. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin. Cancer Res., 7: 1237-1245, 2001
8. Nabel, G. J., Nabel, E. G., Yang, Z. Y., Fox, B. A., Plautz, G. E., Gao, X., Huang, L., Shu, S., Gordon, D., and Chang, A. E. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA. 90: 11307-11311,. 1993
9. Li, S., and Huang, L. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther., 4: 891-900, 1997
10. Li, S., Rizzo, M. A., Bhattacharya, S., and Huang, L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther., 5: 930-937, 1998
11. Li, S., Wu, S. P., Whitmore, M., Loeffert, E. J., Wang, L., Watkins, S. C., Pitt, B. R., and Huang, L. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am. J. Physiol., 276: L796-L804, 1999
12. Nikitin, A. Y., Juarez-Perez, M. I., Li, S., Huang, L., and Lee, W. H. RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/-mice. Proc. Natl. Acad. Sci. USA, 96: 3916-3921, 1999
13. Tan, Y., Li, S., Pitt, B. R., and Huang, L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum. Gene Ther., 10: 2153-2161, 1999
14. Whitmore, M., Li, S., and Huang, L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther., 6: 1867-1875, 1999
15. Miller, S. J., and Hung, M. C. Regulation of HER-2/neu gene expression. Oncol. Rep., 2: 497-503, 1995
16. Yu, D., Matin, A., Xia, W., Sorgi, F., Huang, L., and Hung, M. C. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene, 11: 1383-1388, 1995
17. Yu, D., Suen, T. C., Yan, D. H., Chang, L. S., and Hung, M. C. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc. Natl. Acad. Sci. USA, 87: 4499-4503, 1990
18. Ueno, N. T., Yu, D., and Hung, M. C. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene, 15: 953-960, 1997
19. Yu, D. H., Liu, B. L., Tan, M., Li, J. Z., Wang, S. S., and Hung, M. C. Overexpression of c-erbb-2/neu in breast cancer cells confers increased resistance to taxol via MDR-1-independent mechanisms. Oncogene, 13: 1359-1365, 1996
20. Yu, D., Liu, B., Jing, T., Sun, D., Price, J. E., Singletary, S. E., Ibrahim, N., Hortobagyi, G. N., and Hung, M. C. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene, 16: 2087-2094, 1998
21. Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., and Hung, M. C. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol. Cell, 2: 581-591, 1998
22. Yu, D. H., Scorsone, K., and Hung, M. C. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol. Cell. Biol., 11: 1745-1750, 1991
23. Yu, D., Hamada, J., Zhang, H., Nicolson, G. L., and Hung, M. C. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene, 7: 2263-2270, 1992
24. Chang, J. Y., Xia, W., Shao, R., Sorgi, F., Hortobagyi, G. N., Huang, L., and Hung, M. C. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene. 14: 561-568, 1997
25. Xu, M., Kumar, D., Srinivas, S., Detolla, L. J., Yu, S. F., Stass, S. A., and Mixson, A. J. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum. Gene Ther., 8: 177-185, 1997
26. Lesoon-Wood, L. A., Kim, W. H., Kleinman, H. K., Weintraub, B. D., and Mixson, A. J. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum. Gene Ther., 6: 395-405, 1995
27. Li, B., Li, S., Tan, Y., Stolz, D. B., Watkins, S. C., Block, L. H., and Huang, L. Lyophilization of cationic lipid-protamine-DNA (LPD) complexes. J. Pharm. Sci., 89: 355-364, 2000
28. Tousignant, J. D., Gates, A. L., Ingram, L. A., Johnson, C. L., Nietupski, J. B., Cheng, S. H., Eastman, S. J., and Scheule, R. K. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: Plasmid DNA complexes in mice. Hum. Gene Ther., 11: 2493-2513, 2000
29. Loisel, S., Le Gall, C., Doucet, L., Ferec, C., and Floch, V. Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum. Gene Ther., 12: 685-696, 2001
30. Whitmore, M. M., Li, S., Falo, L., Jr., and Huang, L. Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol., Immunother., 50: 503-514, 2001